Connect Biopharma Holdings Limited (CNTB) Earnings Call Transcripts

Connect Biopharma Holdings Limited's Latest Earnings Call - March 30, 2026

Connect Biopharma Holdings Limited reported its Q1 2026 earnings, highlighting significant developments in its drug rademikibart. The company did not disclose specific revenue or earnings figures, focusing instead on clinical trial results. Management emphasized the promising preliminary results from an IV clinical pharmacology study for asthma and COPD, which could significantly impact the stock. The company also discussed positive Phase III results for atopic dermatitis. No changes in financial guidance were mentioned, but management highlighted a cash runway into the second half of 2027.

Reported metrics

Guidance from management

Management did not provide specific financial guidance but indicated a cash runway into the second half of 2027. They plan to initiate Phase III trials for both acute and chronic indications of rademikibart next year.

What management said

Yes. Excellent question. We will have to delve into that when once the last patient is completed and -- but definitely something that we'll be looking at. I'm currently unaware of any exacerbation in this small cohort of patients over the 28 days. But there may be something interesting in there, and we'll certainly make that known if we find something interesting.

What analysts pressed on

Analysts questioned the variability in FEV1 responses and the potential need for additional bridging studies before Phase III trials. Concerns were also raised about the robustness of the COPD results given the small sample size.

Main topics on the call

• Rademikibart Clinical Trial Results — Connect Biopharma presented preliminary top-line results from an IV study of rademikibart, showing rapid FEV1 improvement in asthma and COPD patients, with effects seen as early as 15 minutes. This positions the drug as ...
• Atopic Dermatitis Phase III Results — The Phase III trial for atopic dermatitis in China showed high response rates, with 87.1% achieving IGA response at 52 weeks and 96.6% achieving EZ75. The safety profile was favorable, with low rates of conjunctivitis co...
• Differentiation from Dupilumab — Rademikibart demonstrated a unique mechanism of action, including faster onset and reduced eosinophil levels compared to dupilumab. This differentiation could enhance its competitive positioning in the market.
• Financial Position and Guidance — Connect Biopharma reported cash and equivalents of $55 million, with a cash runway into the second half of 2027. No specific revenue or earnings guidance was provided.

Read the full Connect Biopharma Holdings Limited transcript (March 30, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 8 Connect Biopharma Holdings Limited earnings call transcripts on record, spanning September 1, 2021 to March 30, 2026. Based on this history, Connect Biopharma Holdings Limited reports annually. The most recent call on file is dated March 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CNTB

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

8

First call

September 1, 2021

Most recent

March 30, 2026

Reporting cadence

annually